The United States has announced a phased tariff plan for imported generic medicines, giving overseas manufacturers two years before steep duties begin. Generic drugs entering the US will remain tariff-free from August 1, 2026, until August 1, 2028. A 100% tariff is then planned for one year, followed by a 200% tariff from August 2029.
The move could hit Indian pharmaceutical companies harder than many exporters because the US is their largest overseas market. India supplies a large share of prescriptions filled by American patients, while generic medicines usually operate on narrow margins. The two-year window offers breathing room, but it also starts a difficult countdown for manufacturers, distributors and healthcare buyers.
What Has The US Announced On Generic Drug Tariffs?
President Donald Trump announced the tariff schedule on July 21, 2026. The plan is aimed at encouraging pharmaceutical companies to move production into the United States rather than continue relying heavily on overseas manufacturing.
The proposed tariff structure includes:
- Zero tariff from August 1, 2026, through July 2028
- A 100% tariff beginning in August 2028
- A 200% tariff from August 2029 onward
- Two years for companies to review US manufacturing options
The announcement is significant because generic medicines account for about nine out of every ten prescriptions dispensed in America. However, they represent a much smaller share of total drug spending because their prices are usually far below branded alternatives.
The official CNBC-TV18 News account on X also posted the phased tariff details, highlighting the initial zero-duty period and the later increases.
This is different from earlier US tariff action focused mainly on branded and patented medicines. Indian generic exporters had previously remained largely protected, but the latest proposal directly targets their biggest product category.
Why Are Indian Pharma Companies More Exposed?
India’s pharmaceutical export model is closely tied to affordable generic medicines. The US purchased nearly 35% of India’s pharmaceutical exports in FY25, while industry estimates suggest more than 95% of those shipments were generics.
An IBEF review of India-US prescription trade shows how central the American market has become for Indian manufacturers.
According to the Pharmaceuticals Export Promotion Council of India, India’s pharmaceutical exports reached $31.11 billion in FY26. The sector has doubled its overseas sales during the past decade, but the US continues to be its most commercially important destination.
Sun Pharma, Dr Reddy’s Laboratories, Cipla, Lupin and Aurobindo Pharma sell substantial volumes in North America. Their exposure will vary by product type. Companies selling specialty medicines, complex generics or products made inside the US may have more room to adjust.
Manufacturers dependent on high-volume, low-price tablets could face heavier pressure. Their products already compete with several suppliers, leaving limited space to increase prices or absorb fresh duties.
Indian pharma shares reflected that concern on July 22. The sector index fell around 2%, while several leading drug stocks declined as investors assessed the longer-term tariff risk.
How Could A 200% Tariff Affect Prices And Medicine Supply?
A 200% duty could make several imported medicines commercially unworkable unless manufacturers, distributors and buyers agree to share the additional cost. Generic companies cannot always absorb tariffs because competition keeps prices low and supply contracts may restrict sudden price revisions.
Some Indian companies may move selected production to the US. Others could work with American contract manufacturers, acquire local plants or renegotiate agreements with distributors. Larger groups may shift attention towards specialty medicines, injectables and complex generics where competition is lower.
However, replacing Indian manufacturing at scale would require factories, regulatory approvals, trained employees, active pharmaceutical ingredients and dependable distribution networks. These arrangements cannot be created quickly.
Indian manufacturers supplied nearly half of all generic prescriptions filled in the US in 2022. Those medicines also generated substantial savings for American patients and the wider healthcare system.
If low-margin suppliers leave certain products before alternative production is ready, shortages could emerge. Older antibiotics, hospital injectables and medicines with only a few approved suppliers may face the greatest risk.
American pharmacies, insurers and hospitals may also pay more. Those higher costs could eventually reach patients through increased insurance premiums, prescription charges or restricted medicine coverage.
What Can Indian Drugmakers Do Before August 2028?
The two-year grace period gives Indian companies time to prepare. Manufacturers will first need to review every US product according to its profit margin, sales volume, production location and supply agreement.
Drugmakers with US Food and Drug Administration-approved plants in America may expand local production. However, manufacturing costs, wages and compliance expenses are generally higher in the US than in India.
Companies may also seek exemptions for essential medicines, shortage-prone drugs or products without an immediate American substitute. Industry bodies could argue that affordable Indian generics reduce US healthcare spending rather than weaken domestic manufacturers.
The Indian government may raise the issue during trade discussions and seek product-specific relief or a slower tariff schedule. Exporters could also expand further into Europe, Africa, Latin America and Asian markets to reduce dependence on one country.
Companies with strong finances, specialised portfolios and existing American plants may adjust faster. Smaller manufacturers could require partnerships, contract production deals or new regional markets to protect revenue.
Frequently Asked Questions
When will US tariffs on imported generic drugs begin?
The 100% tariff is planned for August 2028, after a two-year zero-tariff transition period begins.
When could the tariff rise to 200%?
The proposed 200% tariff would start in August 2029, following one year at 100% duty.
Why are Indian pharmaceutical companies vulnerable?
They supply large generic volumes to America, where intense competition keeps manufacturer profit margins relatively thin.
Could medicine prices rise in the United States?
Yes, higher import costs may reach pharmacies, insurers, hospitals and patients when suppliers cannot absorb tariffs.
Can Indian companies avoid tariffs by manufacturing locally?
US production may reduce exposure, but compliant facilities require capital, approvals, workers and considerable construction time.
